Core Viewpoint - Weigao Blood Purification is planning a major asset restructuring by acquiring 100% equity of Weigao Purui Pharmaceutical Packaging Co., Ltd. through a share issuance, which is expected to constitute a significant asset restructuring and related party transaction [4][5]. Group 1: Transaction Details - The transaction is currently in the planning stage, and there are uncertainties regarding the details [5]. - The stock of Weigao Blood Purification will be suspended from trading starting October 20, 2025, for a period not exceeding 10 trading days to protect investor interests [5]. - Weigao Purui was established on September 13, 2018, with a registered capital of 106 million yuan, and its business scope includes the production and sales of medical devices and packaging materials [5][6]. Group 2: Shareholding Structure - The largest shareholder of Weigao Purui is Shandong Weigao Group Medical Polymer Co., Ltd., holding 94% of the shares [6]. - Weigao Group is the ultimate controlling shareholder of Weigao Blood Purification, which was listed on the Shanghai Stock Exchange on May 19, 2025, and focuses on the research, production, and sales of blood purification medical products [6]. Group 3: Financial Performance - For the first half of 2025, Weigao Blood Purification reported a revenue of 1.765 billion yuan, an increase of 8.52% year-on-year, and a net profit attributable to shareholders of 220 million yuan, up 10.11% year-on-year [6].
603014，重大资产重组！下周一起停牌！